ClinicalTrials.gg
Not yet recruitingNCT07855991Updated Oct 20, 2026

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment

A Phase 1 interventional study of Sonrotoclax in Hepatic Impairment and Healthy Adult Participants, sponsored by BeOne Medicines. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Other

Updated Oct 20, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this study is to understand how the body processes sonrotoclax in adults with serious liver problems compared to adults with normal liver function.

Read the detailed description

Sonrotoclax is a drug which blocks a protein called B-cell lymphoma-2 (Bcl-2). Bcl-2 helps certain blood cancer cells live and grow. By blocking Bcl-2, sonrotoclax may slow or stop cancer cell growth and help them die.

The purpose of this study is to look at the safety and blood levels of sonrotoclax in adults with serious liver problems. Results from this study will help researchers understand if dose changes are needed for adults with liver problems.

Participants will take one dose of sonrotoclax by mouth with food and remain in the clinic for about 3 days of monitoring. This study is an open-label study, meaning that both participants and study doctors will know what study drug/treatment is given.

The study will enroll approximately 12 adults in the United States (6 adults with serious liver problems and 6 adults with normal liver function).

The overall time to participate in this study is approximately 4 weeks. Participants will make regular visits to the clinic for health checks, blood tests, sonrotoclax administration and monitoring, and follow-up.

02

Conditions studied

  • Hepatic Impairment
  • Healthy Adult Participants

Keywords

  • sonrotoclax
  • Pharmacokinetics
  • BCL2i
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

General Inclusion Criteria:

  • (BMI) between 18.0 and 42.0 kg/m\^2, inclusive
  • Generally stable health (except for hepatic impairment in hepatically impaired participants) as determined by the Investigator based on medical evaluation at Screening and Check-in, with no findings that would interfere with study participation
  • Female participants of non- who meet any of the following criteria: surgically sterile or
  • Male participants are eligible if vasectomized or if they agree to the use of barrier with other highly effective methods if sexually active with women of childbearing potential, during study treatment and for at least 7 days after the dose of study drug

Inclusion Criteria for Severe Hepatic Impairment Group:

  • Severe hepatic dysfunction per National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria (serum total > 3 × [ULN], any [AST])
  • Clinically stable hepatic disease, in the opinion of the investigator, with no clinically significant worsening of hepatic function within 4 weeks prior to dosing

Inclusion Criteria for Normal Hepatic Function Group:

  • Normal hepatic function, including total bilirubin ≤ ULN and AST ≤ ULN
  • Absolute B-cell count of > 150 cells/μL

General Exclusion Criteria:

  • Any clinically significant disease or condition that, in the opinion of the Investigator, would interfere with study participation, safety, or evaluation of study results
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator
  • Evidence of any infections (bacterial, viral, fungal, parasitic) within 2-4 weeks prior to the first dose of study drug, as determined by the investigator (or designee)
  • Positive urine drug screen or alcohol urine/breath test/blood results at screening or check-in
  • History of alcoholism or drug/chemical abuse within the last 2 years

Exclusion Criteria for Severe Hepatic Impairment Group:

  • Acute hepatic disease or rapidly deteriorating hepatic function
  • History of liver transplantation
  • Previously diagnosed hepatocellular carcinoma, or history of cholestatic liver disease or biliary sepsis within the past 2 years

Exclusion Criteria for Normal Hepatic Function Group:

  • Any known or suspected hepatic disease
  • Clinically significant abnormalities in liver function tests at Screening
  • Require ongoing use of prescription or nonprescription medications, including herbal supplements (unless the medication is not expected to interfere with the pharmacokinetics, safety, or tolerability of the study drug)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Group 1: Severe Hepatic Impairment

    Participants with severe hepatic impairment will receive a single dose of sonrotoclax on Day 1.

    Drug: Sonrotoclax

  • Experimental
    Group 2: Normal Hepatic Function

    Participants with normal hepatic function will receive a single dose of sonrotoclax on Day 1.

    Drug: Sonrotoclax

Interventions

  • Single dose administered orally.

    Also known as: BGB-11417, BEQALZI

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of Sonrotoclax

    Time frame: Days 1-3

  2. AUC from time 0 extrapolated to infinity (AUC0-inf) of Sonrotoclax

    Time frame: Days 1-3

  3. Maximum observed plasma concentration (Cmax) of Sonrotoclax

    Time frame: Days 1-3

  4. Time to reach maximum observed plasma concentration (Tmax) of Sonrotoclax

    Time frame: Days 1-3

  5. Apparent terminal elimination half-life (t1/2) of Sonrotoclax

    Time frame: Days 1-3

  6. Apparent oral clearance (CL/F) of Sonrotoclax

    Time frame: Days 1-3

  7. Apparent volume of distribution (Vz/F) of Sonrotoclax

    Time frame: Days 1-3

  8. Fraction unbound (Fu) of Sonrotoclax

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of participants with TEAEs and SAEs, including adverse events with onset or increase in severity level on or after single dose administration.

    Time frame: Approximately 10 days

  2. Number of Participants with Laboratory Abnormalities

    Number of participants with laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results. Clinical laboratory values will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 for selected laboratory analytes.

    Time frame: Approximately 3 days

  3. Number of Participants with Clinically Significant Vital Signs Measurements

    Vital signs include pulse rate, body temperature, and blood pressure.

    Time frame: Approximately 3 days

  4. Number of Participants with Clinically Significant Physical Examination Findings

    Number of participants with clinically significant physical examination findings, including new or worsened clinically significant abnormalities.

    Time frame: Approximately 3 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 2, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Feb 8, 2027
CompletionEst.
Feb 8, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Nov 2026
Oct 20, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 20, 2026
    Start date Oct 15, 2026→Nov 2026
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855991
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 8, 2027 (estimated)
Completion
Feb 8, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
1.877.828.5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion